I am very well aware that it is all about the money.
Here is part of a statement on the CCSVI Worldwide Victory website that I made about Biogen and how they minimize the risk:
So, we have a company that brings in $1 billion annually off of Tysabri sales. Are we to believe this was an oversight on the part of Biogen? No way! This was strategically planned! After European regulators disclosed a much higher number of PML cases than expected, they devised a plan to convince the customer that benefit was greater than risk. Here in this conference call between Biogen and it's investors you can hear of this plan for yourselves: Feb. 9, 2010 <shortened url
Biogen knew when they made the decision to produce this webcast that they would be in violation, but they didn't care. Over four months after the violation was said and done, they simply received a letter requesting they immediately cease the dissemination. Unbelievable!
From the Tysabri website:
How many cases of PML have there been?
* In TYSABRI clinical trials, 3 cases of PML occurred (2 in MS trials, and 1 in Crohn's disease trials)
* The two MS patients who developed PML were taking TYSABRI and AVONEX at the same time. The one patient with Crohn's disease had a weakened immune system
* There have also been reports of PML in patients who have taken TYSABRI as a monotherapy since TYSABRI was reintroduced to the market in 2006
* The absolute risk for PML in patients treated with TYSABRI cannot be precisely estimated, for more information contact your healthcare provider.
This too, is unbelievable! They don't disclose the statistics every month because they are concerned for the patient, they disclose the statistics because they must. The statement above, which is on their website, shows how far they are willing to go to cover the risk of PML.